Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Prostate CancerProstatic Neoplasms
Interventions
DRUG

Docetaxel

"One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days."

DRUG

Imatinib Mesylate

"One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days."

Trial Locations (3)

10016

Bellevue Hospital, New York

NYU Clinical Cancer Center, New York

NYU Tisch Hospital, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

NYU Langone Health

OTHER